FDA Pulls 16 Unused Generic Drug Approvals
Published Date: 6/3/2026
Notice
Summary
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
FDA Withdraws 16 Generic Approvals
The FDA is withdrawing approval of 16 abbreviated new drug applications (ANDAs) at the request of the applicants. This withdrawal takes effect on July 6, 2026 and applies to the entire application and all strengths and dosage forms.
Post-Withdrawal Sales Are Prohibited
After July 6, 2026, introducing into interstate commerce any of the listed products without an approved ANDA violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act. Firms that distribute or attempt to market these products without approval would be acting unlawfully.
Existing Inventory May Still Be Dispensed
Drug products listed in the notice that are in inventory on July 6, 2026 may continue to be dispensed until the inventories are depleted or the products reach their expiration dates, whichever occurs first. This allows existing stock at pharmacies or wholesalers to be used up after the approval withdrawal date.
Withdrawals Are Without Prejudice
The FDA states that withdrawal of approval under 21 CFR 314.150(c) is without prejudice to refiling. That means applicants may refile ANDAs later if they choose to pursue approval again.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11060 — Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities-Questions and Answers; Revised Draft Guidance for Industry; Availability
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
2026-11101 — Third Annual Animal Drug User Fee Educational Conference; Public Meeting
The FDA is hosting its Third Annual Animal Drug User Fee Educational Conference on July 7, 2026, to help drug makers and animal health experts understand the new animal drug approval process. This free event is both in-person and online, making it easy to join. Stakeholders should register early and can send feedback within 90 days after the meeting to help shape future policies and fees.
2026-11054 — Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help companies making gene therapy products that use genome editing. It shows how to use what’s already known to speed up development and get safer, smarter treatments to patients faster. If you’re in this field, send your feedback by September 1, 2026, so your voice shapes the final rules—saving time and money down the road!
2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
2026-10908 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Rigid Sterilization Container With Electronic Monitoring
The FDA is officially classifying rigid sterilization containers with electronic monitoring as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps hospitals and medical device makers get these safer, smarter containers to patients faster and easier. The new rules took effect June 1, 2026, making it simpler and potentially less costly to bring these devices to market.
2026-10873 — Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability
The FDA is rolling out a new draft guide to help cancer drug makers speed up safety testing for biologic and conjugated medicines. This plan cuts down on extra animal testing and uses smarter methods learned during the COVID-19 pandemic. Drug developers should send their feedback by July 31, 2026, to shape the final rules and save time and money in bringing new cancer treatments to patients.
Previous / Next Documents
Previous: 2026-11060 — Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities-Questions and Answers; Revised Draft Guidance for Industry; Availability
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
Next: 2026-11063 — Proposed Exemption Involving the Abiomed Retirement Savings Plan Located in Danvers, MA
The Abiomed Retirement Savings Plan in Danvers, MA, wants permission to hold special financial rights called contingent value rights (CVRs) and get payments from them. Without this okay, these moves would break some important retirement rules. If approved, the exemption starts retroactively from November 15, 2022, and folks have until July 20, 2026, to share their thoughts or ask for a hearing.